In 2021, Pfizer — the manufacturer of Chantix — announced a voluntary nationwide recall of all lots of Chantix 0.5 mg and 1 mg tablets distributed in the United States, because testing revealed the presence of a nitrosamine impurity, N‑nitroso‑varenicline, at or above the company’s and U.S. Food and Drug Administration (FDA) interim acceptable intake limits.

Nitrosamines are a class of chemical compounds — many of them considered probable or possible carcinogens. The concern is that prolonged exposure to elevated levels of nitrosamines may increase the risk of cancer in humans.

Pfizer originally recalled several lots in mid-2021, but as testing continued, they expanded the recall. On September 16, 2021, Pfizer formally recalled all lots of Chantix tablets in the U.S. at the “patient (consumer/user) level.”

According to the recall announcement, the presence of N-nitroso-varenicline exceeded the company’s Acceptable Daily Intake (ADI) threshold. Because of this, Pfizer and FDA judged that continuing to distribute those lots posed an “unnecessary risk.”

Despite this, both Pfizer and FDA stressed that there is no evidence of actual cancer cases linked to Chantix use. The risk was described as theoretical — a long-term risk if patients were exposed repeatedly to above-threshold nitrosamine levels over time.

Because of the recall, Pfizer also paused the release of new Chantix to the U.S. market until they could assure nitrosamine levels were below acceptable limits.

The immediate guidance from FDA and Pfizer was that patients should not abruptly stop taking Chantix — at least not without consulting their doctor or pharmacist. The reason: the medication is used for smoking cessation, and stopping suddenly could undermine quitting efforts; moreover, there was no immediate health emergency despite the recall.

Instead, patients were recommended to contact their healthcare providers to check if their pills came from affected lots, and if needed, to discuss alternative treatments or replacement medications.

Health professionals and pharmacies were instructed to quarantine any recalled lots, stop distribution, and follow return protocols — especially wholesalers or distributors holding inventory.

At the same time, FDA recognized the risk of a drug shortage due to the recall. To mitigate this, the agency allowed — on a temporary, discretionary basis — the distribution of varenicline from alternative suppliers, even if those products had nitrosamine levels between FDA’s “acceptable intake” and “interim acceptable” limits, while urging manufacturers to reduce impurities.

Nitrosamines are not unique to pharmaceuticals. They are fairly common in many foods and environmental sources: water, certain cured or grilled meats, dairy products, and some vegetables.

However, regulatory limits exist precisely to ensure that exposure remains within a level considered “acceptable” given current evidence. The concern with Chantix was that certain lots exceeded those limits — which, over long-term ingestion, could theoretically raise lifetime cancer risk.

Importantly, the recall notice also emphasized that the benefits of using Chantix to quit smoking — a habit strongly linked to lung cancer, cardiovascular disease, and other serious illnesses — still outweigh the theoretical risk posed by the nitrosamine impurity. In their words: for many patients, the health gains from quitting smoking remain greater than the potential hazard from the impurity.

Thus, while regulatory action was warranted to ensure drug quality and minimize theoretical risks, the decision to recall did not stem from detected harm, but from quality-control and long-term safety concerns.

Because of the recall, the supply of Chantix in the U.S. was immediately affected — distribution was paused, and wholesalers, pharmacies, and distributors were instructed to stop handling recalled lots.

To prevent shortage of smoking-cessation options, FDA allowed other varenicline products (from alternative suppliers) that met interim nitrosamine criteria to be distributed — temporarily — while manufacturers worked to lower impurities.

For patients and providers, this meant reviewing treatment plans. Those using Chantix needed to check their lot numbers; new prescriptions might shift to alternative varenicline sources or to other cessation aids. The recall highlighted how even long-established medications can be subject to rigorous quality control and that oversight continues long after approval.

What we know for sure: Chantix was recalled because of unacceptable levels of a nitrosamine impurity, N-nitroso-varenicline, which could hypothetically raise cancer risk in the long term if consumed chronically at high rates. The recall was voluntary and carried out by Pfizer with the cooperation of the FDA.

What we do not know: there is no evidence that patients who took recalled Chantix developed cancer or suffered adverse events directly linked to the nitrosamine contamination. The risk was theoretical.

The recall nevertheless underscores a broader and important reality: even widely used and long-approved medications are subject to ongoing safety and manufacturing oversight. The presence of impurities may emerge only years after approval — and regulators and manufacturers must remain vigilant. For patients, the incident is a reminder to stay informed, check medication lots when recalls are issued, and consult healthcare providers for safe alternatives if needed.

For public health, the Chantix recall reinforces the importance of balancing risks and benefits: using a medication to quit smoking — which itself carries a high risk of cancer and other diseases — might still be safer than continuing to smoke, even in the face of theoretical chemical-impurity risks. As FDA put it, “the health benefits of stopping smoking outweigh the cancer risk from the nitrosamine impurity in varenicline.”